Merck Bolsters Covid-19 Pipeline with OncoImmune Acquisition Acquisitions, Business, Coronavirus Disease (COVID-19) Pandemic, COVID-19 therapeutic candidates, Deals, Immunomodulatory Agents, Interim Analysis, Product Pipeline, Retirements, Vaccines Merck acquired Maryland-based OncoImmune and the Covid-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis. Read more November 23, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/11/Merck-Bolsters-COVID-19-Pipeline-with-OncoImmune-Acquisition-BioSpace-11-23-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-11-23 10:37:062020-11-23 15:34:46Merck Bolsters Covid-19 Pipeline with OncoImmune Acquisition